推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 全球農(nóng)藥市場以前六大巨頭為主導。全球農(nóng)藥類企業(yè)主要分為兩種商業(yè)模式：
一種是農(nóng)藥創(chuàng)制類企業(yè)商業(yè)模式，由于農(nóng)藥新產(chǎn)品的創(chuàng)制難度大，對技術(shù)和投入要求高，但是新藥在專利保護期內(nèi)擁有極高的利潤率。所以六大跨國巨頭實行農(nóng)藥創(chuàng)制類企業(yè)商業(yè)模式，擁有強大的研發(fā)能力和營銷能力，形成利潤到研發(fā)的良性循環(huán)。
另一種是農(nóng)藥仿制類企業(yè)商業(yè)模式，仿制類企業(yè)主要生產(chǎn)專利到期的農(nóng)藥和無專利農(nóng)藥，憑借生產(chǎn)能力和控制成本，利用新設(shè)備的投入和工藝優(yōu)化來占領(lǐng)市場。
海外巨頭產(chǎn)能投入減少，我國農(nóng)藥產(chǎn)業(yè)地位愈發(fā)重要。2010年以來，我國的農(nóng)藥產(chǎn)業(yè)已呈現(xiàn)出鮮明的出口導向型特征，而與此同時，海外巨頭在固定資產(chǎn)上的投入增速卻大大減緩，甚至出現(xiàn)了固定資產(chǎn)的收縮。在經(jīng)濟全球化形成的精細分工中，逐漸形成了國外創(chuàng)新型農(nóng)藥公司進行研發(fā)、而由中國企業(yè)對農(nóng)藥原藥進行定制或是仿制生產(chǎn)并向外出口的經(jīng)濟模式。2016年，我國農(nóng)藥原藥出口量達到140萬噸，比上年大增19.2%，創(chuàng)下歷史新高，預計在產(chǎn)能轉(zhuǎn)移的大背景下，未來五年我國農(nóng)藥出口仍將保持增長態(tài)勢。
